Europe buys 200 million doses of the new Novavax vaccine

© Reuters

The European Commission and the American biotechnology company Novavax have reached an agreement: the European Union will buy 100 million doses of the new vaccine, and there is also an option for another 100 million doses. This is stated in the report of the Chairman of the Committee Ursula von der Leyen and the report of the biotechnology company.

The European Union concluded the so-called Advance Purchase Agreement (APA) with the company. APA is a kind of purchase promise, including prepayment. In this way, the European Union funds part of the production and development of vaccines. Novavax is the seventh product with which the European Commission has signed a deal to supply vaccines.

Here is the content listed from a social media network that you want to write or read cookies. You have not given permission for this.

Currently, the EU will buy 100 million doses, and there is an option to get an additional 100 million doses. The new vaccine is intended to complement the existing vaccination portfolio in the European Union, especially now that the delta variant is increasingly prevalent. In a statement, Von Der Leyen said the vaccine is effective against variants. This contract is an additional guarantee to protect our residents. This enhances our broad vaccine portfolio, for the benefit of Europeans and our partners around the world.”

© AP

Vaccines from Novavax are expected to be delivered this year, but also in 2022 and 2023. They still need to be approved by the European Medicines Agency (EMA). It is a “protein vaccine”. Because of the association, it is cheaper to produce such vaccines than their mRNA counterparts from Pfizer and Moderna. It should also be kept less cold.

See also  Extreme heat wave in Spain lasts at least nine days: not sure yet if record 47.4 degrees will fall | Weather News

In a Phase 3 study of nearly 30,000 adults in the United States and Mexico, NVX-CoV2373 (Novavax vaccine ed.) 100 per cent protection against moderate to severe disease and 90.4 per cent overall efficacy,” Nova said. “In a UK Phase III study of nearly 15,000 adults, NVX-CoV2373 demonstrated an overall efficacy of 89.7% and greater efficacy than 96% against the parent strain of the virus.”

What about the fifth Sputnik?

It is uncertain whether the agency will allow the Russian Sputnik V vaccine, according to committee chair Ursula von der Leyen. “So far, the product has failed to provide sufficient valid information to demonstrate safety,” the German told Redaktionsnetzwerk Deutschland (RND).

According to the producer itself, the Russian vaccine has already been approved in 69 countries around the world. Within the European Union, this is the case in Hungary and Slovakia, without the green light from the EMA. Recently, Russia hoped to receive a European order by the fall. The EMA has been testing the vaccine since March. It depends on his judgment on whether the European Commission will officially give the green light to launch the Sputnik V in the next step. Russia did not allow foreign vaccines in its country.

Russian Foreign Minister Sergei Lavrov said that EMA employees are in direct contact with the Russian Ministry of Health and Trade. “According to our information, there are no objections to the vaccine and its effectiveness,” Lavrov told the newspaper Komsomolskaya Pravda.

Denton Watson

"Friend of animals everywhere. Evil twitter fan. Pop culture evangelist. Introvert."

Leave a Reply

Your email address will not be published. Required fields are marked *